Synonyms: ARV771
Compound class:
Synthetic organic
Comment: ARV-771 is a small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology [1]. It targets the BET domain proteins BRD2/3/4 for VHL E3 ligase-mediated ubiquitination and proteasomal degradation. This mechanism effects suppression of the androgen receptor (AR) protein level and AR signalling. ARV-771 is efficacious in vivo, as demonstrated in two different mouse models of castration-resistant prostate cancer (CRPC).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
ARV-771 degrades BRD2/3/4 in cellular assays with a DC50 <5 nM and promotes significantly greater apoptotic cell death than a BET inhibitor alone [1]. It reduces BET function with an IC50 <1 nM which is more potent than the BET inhibitor (+)-JQ1, although its binding affinity (Kd) is similar to that reported for (+)-JQ1. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|